Cardiac biomarkers and chronic renal diseases

Bratislava Medical Journal

Volumn 109, Issue 8, 2008, Pages 341-344

  Valocikova, I ^a   Kristofova, B ^a   Valocik, G ^a  

^a L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

Author keywords

Cardiac biomarkers; Chronic kidney diseases; Chronic renal failure; End stage renal disease

Indexed keywords

ARGININE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DRUG DERIVATIVE; HOMOCYSTEINE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; TROPONIN;

ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; HUMAN; REVIEW;

ANIMALS; ARGININE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; NATRIURETIC PEPTIDE, BRAIN; TROPONIN;

EID: 57049151798     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens 2005; 14: 1-6.
2. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adults. J Amer Soc Nephrol 2005; 16: 2134-2140.
3. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908-1919.
4. Mallamaci F, Tripepi S, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330-2337.
5. Panichi V, Migliori M, De Pietro S et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002; 61: 594-600.
6. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm J, Lindholm B, Stenvikel B. Associations between circulating inflammatory markers and residual renal function in CRF patients. Amer J Kidney Dis 2003; 41: 1212-1218.
7. Tonneli M, Saks F, Pfeffer M, Jhangri GS, Curhan G. Cholesterol and Reccurent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
8. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesions molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Amer Soc Nephrol 2005; 16 (Suppl 1): S83-S88.
9. Roberts WL. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice. Laboratory tests available to assess inflammation - performance and standardization: a background paper. Circulation 2004; 110: 572-576.
10. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 2002; 325: 1202.
11. Mallamaci F, Zoccali C, Tripepi G, Fermo J et al. CREED Investigators. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 603-614.
12. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. J Amer Med Ass 2007; 298: 1212-1214.
13. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease. Effect on Cardiovascular System. Circulation 2007; 116: 85-97.
14. Cooke JP. Asymmetrical dimethylarginine: the uber marker? Circulation 2004; 109: 1813-1818.
15. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
16. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risk modeling approach. J Amer Soc Nephrol 2005; 16: 2449-2455.
17. Böger RH, Bode-Böger SM, Phivtong-ngam L et al. Restoring vascular NO formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disesase. J Amer Coll Cardiol 1998; 32: 1336-1344.
18. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123-2128.
19. Bozbas H, Yildirir A, Muderrisoglu H. Cardiac Enzymes, Renal Failure and Renal Transplantation. Clinical Medicine &Research 2006; 1: 79-84.
20. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Amer Coll Cardiol 2002; 40: 2065-2071.
21. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 2001; 94: 993-996.
22. Mallamaci F, Zoccali C, Parlongo S et al. Cardiovascular Risk Extended Evaluation in Dialysis Investigators. Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. Kidney Int 2002; 62: 1884-1890.
23. Duman D, Tokay S, Toprak A, Duman D, Iktay A, Ozener IC, Unay O. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 962-967.
24. Iliou MC, Fumeron C, Benoit MO. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Amer J Kidney Dis 2003; 42: 513-523.
25. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-2945.
26. Beciani M, Tedesco A, Violante A, Cipriani S, Azzarito M, Sturniolo A, Splendiali G. Cardiac troponin I (2nd generation assay) in chronic hemodialysis patients: prevalence and prognostic value. Nephrol Dial Transplant 2003; 18: 942-946.
27. Apple FD, Murakami MM, Pearce LA, Herzog CA. Multi-Biomarker Risk Stratification of N-terminal Pro-B-type Natriuretic Peptide, High Sensitivity C-Reactive Protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-cause Death. Clin Chem 2004; 50: 2279-2285.
28. Cameron SJ, Geen GB. Cardiac Biomarkers in Renal Disease: The Fog Is Slowly Lifting. Clin Chem 2004; 50: 2233-2235.
29. Joffy S, Rossner MH. Natriuretic peptides in ESRD. Amer J Kidney Dis 2005; 46: 1-10.
30. Levin E, Gardner D, Samson K. Natriuretic peptides. New Engl J Med 1998; 339: 321-328.
31. Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Amer Soc Nephrol 2001; 12: 1508-1515.
32. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholis MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: f1126-1130.
33. Krajcovicova-Kudlackova M et al. Nutritional determinants of plasma homocysteine. Bratisl Lek Listy 2007; 108 (12): 510-515.